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Objective
Methotrexate (MTX) is the most commonly used disease
modifying antirheumatic drug (DMARD) in juvenile idio-
pathic arthritis (JIA), especially in polyarticular arthritis.
At present no reliable prediction of individual response to
MTX can be made. Identification of factors that influence
the response to MTX could be helpful in realizing the opti-
mal treatment for each individual patient.
Materials and methods
A cohort of 118 JIA patients that were treated with MTX
was studied retrospectively. Clinical parameters and gen-
otypic data of 6 single nucleotide polymorphisms (SNP)
in 5 genes related to the mechanism of action of MTX were
compared between MTX responders and non-responders
using a multivariate regression analysis.
Results
The time-to-start-MTX (time from diagnosis to start MTX
treatment), the starting dosage and the baseline physi-
cian's global assessment were significantly related to the
response to MTX at 6 months after initiation in a multivar-
iate regression analysis. No effect of the starting dose on
the response to MTX was found when correcting for differ-
ent treatment strategies in different subtypes. The baseline
physician's global assessment was directly related to the
time-to-start-MTX. Subgroup analyses showed that time-
to-start-MTX was consistently significantly associated with
response to MTX. A non significant trend towards an
increased probability to respond was seen when the time-
to-start-MTX was ≤1 years.
Conclusion
In children with JIA, the time-to-start-MTX appears to be
an important factor for the MTX response. In this study we
show that an early MTX treatment (≤1 year) is associated
with an increased efficacy of MTX on short term.
from 15th Paediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008
Published: 15 September 2008
Pediatric Rheumatology 2008, 6(Suppl 1):P46 doi:10.1186/1546-0096-6-S1-P46
<supplement> <title> <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p> </title> <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.ped-rheum.com/content/6/S1/P46
© 2008 Albers et al; licensee BioMed Central Ltd. 